Psychedelic Alpha Medical Advisor Twitter Linkedin Part of our Year in Review series Psychedelic Alpha’s Medical Advisor, Michael Haichin, looks back at five of the most impressive psychedelic clinical trials of 2022. A word of advice: Haichin is a footnote fanatic, so be sure to read them as you go. Much of the contemporary psychedelic re-emergence is driven by the desire to determine whether…


Previous articleSmall Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology
Next articleCOMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023